Literature DB >> 28711447

The Transition From Hypertension to Heart Failure: Contemporary Update.

Franz H Messerli1, Stefano F Rimoldi2, Sripal Bangalore3.   

Abstract

Longstanding hypertension ultimately leads to heart failure (HF), and, as a consequence most patients with HF have a history of hypertension. Conversely, absence of hypertension in middle age is associated with lower risks for incident HF across the remaining life course. Cardiac remodeling to a predominant pressure overload consists of diastolic dysfunction and concentric left ventricular (LV) hypertrophy. When pressure overload is sustained, diastolic dysfunction progresses, filling of the concentric remodeled LV decreases, and HF with preserved ejection fraction ensues. Diastolic dysfunction and HF with preserved ejection fraction are the most common cardiac complications of hypertension. The end stage of hypertensive heart disease results from pressure and volume overload and consists of dilated cardiomyopathy with both diastolic dysfunction and reduced ejection fraction. "Decapitated hypertension" is a term used to describe the decrease in blood pressure resulting from reduced pump function in HF. Progressive renal failure, another complication of longstanding hypertension, gives rise to the cardiorenal syndrome (HF and renal failure). The so-called Pickering syndrome, a clinical entity consisting of flash pulmonary edema and bilateral atheromatous renovascular disease, is a special form of the cardiorenal syndrome. Revascularization of renal arteries is the treatment of choice. Most antihypertensive drug classes when used as initial therapy decelerate the transition from hypertension to HF, although not all of them are equally efficacious. Low-dose, once-daily hydrochlorothiazide should be avoided, but long-acting thiazide-like diuretics chlorthalidone and indapamide seem to have an edge over other antihypertensive drugs in preventing HF.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HFpEF; Pickering syndrome; antihypertensive therapy; cardiorenal syndrome; hypertensive heart disease; left ventricular hypertrophy

Mesh:

Substances:

Year:  2017        PMID: 28711447     DOI: 10.1016/j.jchf.2017.04.012

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  84 in total

Review 1.  Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation.

Authors:  Alan J Mouton; Xuan Li; Michael E Hall; John E Hall
Journal:  Circ Res       Date:  2020-03-12       Impact factor: 17.367

2.  Non-invasive thermal imaging of cardiac remodeling in mice.

Authors:  Rafael Y Brzezinski; Zehava Ovadia-Blechman; Nir Lewis; Neta Rabin; Yair Zimmer; Lapaz Levin-Kotler; Olga Tepper-Shaihov; Nili Naftali-Shani; Olga Tsoref; Ehud Grossman; Jonathan Leor; Oshrit Hoffer
Journal:  Biomed Opt Express       Date:  2019-11-08       Impact factor: 3.732

Review 3.  Pulsatile arterial haemodynamics in heart failure.

Authors:  Thomas Weber; Julio A Chirinos
Journal:  Eur Heart J       Date:  2018-11-14       Impact factor: 29.983

Review 4.  Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.

Authors:  Akanksha Agrawal; Mario Naranjo; Napatt Kanjanahattakij; Janani Rangaswami; Shuchita Gupta
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 5.  Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

Authors:  Aakash Bavishi; Ravi B Patel
Journal:  Heart Fail Clin       Date:  2020-07-21       Impact factor: 3.179

Review 6.  The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.

Authors:  Nicola Riccardo Pugliese; Stefano Masi; Stefano Taddei
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

Review 7.  Integrating Measures of Myocardial Fibrosis in the Transition from Hypertensive Heart Disease to Heart Failure.

Authors:  R Brandon Stacey; W Gregory Hundley
Journal:  Curr Hypertens Rep       Date:  2021-04-21       Impact factor: 5.369

Review 8.  The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.

Authors:  Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2019-06-20       Impact factor: 17.367

9.  Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life.

Authors:  Laura P Cohen; Eric Vittinghoff; Mark J Pletcher; Norrina B Allen; Sanjiv J Shah; John T Wilkins; Patricia P Chang; Chiadi E Ndumele; Anne B Newman; Diane Ives; Mathew S Maurer; Elizabeth C Oelsner; Andrew E Moran; Yiyi Zhang
Journal:  J Card Fail       Date:  2020-11-22       Impact factor: 5.712

10.  Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.

Authors:  Jun Gu; Yu-Qi Fan; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-15       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.